This HTML5 document contains 139 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n5http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q46708832
rdf:type
wikibase:Item
schema:description
scientific article published in September 2005 artigo científico 2005年学术文章 บทความทางวิทยาศาสตร์ scientific article published in September 2005 naučni članak научна статия wissenschaftlicher Artikel სამეცნიერო სტატია vitenskapelig artikkel 2005年學術文章 2005 nî lūn-bûn articol științific artículu científicu научни чланак artikulong pang-agham 2005年學術文章 tudományos cikk مقالة علمية نشرت في سبتمبر 2005 2005년 논문 2005年學術文章 научни чланак 2005年学术文章 2005年の論文 επιστημονικό άρθρο article científic সেপ্টেম্বর ২০০৫-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ article scientific 2005年學術文章 artigo científico bài báo khoa học наукова стаття, опублікована у вересні 2005 artículo científico publicado en 2005 vědecký článek teaduslik artikkel 2005年学术文章 videnskabelig artikel scienca artikolo 2005年學術文章 artikull shkencor мақолаи илмӣ научная статья artykuł naukowy 2005年学术文章 vetenskaplig artikel scientific article published in September 2005 bilimsel makale article scientifique artikel ilmiah artigo científico 2005年学术文章 מאמר מדעי articolo scientifico vitskapeleg artikkel tieteellinen artikkeli wetenschappelijk artikel 2005年学术文章 vedecký článok
p:P577
wds:Q46708832-26AE68C9-A146-4C02-A8FB-66277B31A708
wdt:P577
2005-09-01T00:00:00Z
p:P407
wds:Q46708832-F5449F03-6324-4A9B-B240-0CD7EAE2A20C
wdt:P407
wd:Q1860
p:P2093
wds:Q46708832-D2D57273-3367-424F-A60D-93CE1455A325 wds:Q46708832-CCFB599D-B93A-4B69-BD37-74F010DB5E0D wds:Q46708832-E994E714-8C4C-4CAD-BA7F-3A5690B83482 wds:Q46708832-F75DD33B-35E7-4B10-A07F-B5CD52430C73 wds:Q46708832-18ABA01D-4970-4908-835E-92E99C97E18C wds:Q46708832-31950750-AC45-4695-BD83-75355038F4DC wds:Q46708832-410C063C-D00D-4F51-BB69-61BD436CCAD8 wds:Q46708832-54D9A6A8-1990-4F54-88F9-D4B4CF70E2EC wds:Q46708832-7CED9DFE-4197-41DF-853D-5C6D5492EA95 wds:Q46708832-9EC21C83-AD1B-4207-85C5-33CF79777F5D wds:Q46708832-BC773E00-A824-4119-918A-834D7231F01A wds:Q46708832-A7BFAB8C-A0BE-4BBB-84AF-B52D7ADAD1B9 wds:Q46708832-B6233DE4-9D5E-4D3F-9753-026A3E12C447
wdt:P2093
Keith A Fox Christian W Hamm Marcus D Flather Michael A Weber Mark A Creager Jean-Louis Mas CHARISMA Investigators Henry R Black Joan Booth Werner Hacke Thomas A Pearson J Donald Easton Koon-Hou Mak
rdfs:label
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
skos:prefLabel
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
schema:name
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
p:P50
wds:Q46708832-0D22C0D6-AC83-40FC-A4BE-02EA9CB17E63 wds:Q46708832-0D53E39B-E2B7-4056-A695-A3831A28AD6C wds:Q46708832-96188D48-0DB6-4B41-8214-3B76B0A9EFA6 wds:Q46708832-66796B06-0552-405C-8B69-922467E8A47E wds:Q46708832-692FC7CA-1414-4254-A1BC-D7423A0D3400 wds:Q46708832-723E584B-D2C2-46AB-AE1D-3B26295CA93C wds:Q46708832-C360C4E1-D464-4FE2-A313-80EFC5BE533E wds:Q46708832-D8ED7AAC-4DC9-4815-AF73-8C942C8B08AE wds:Q46708832-E3764B71-E678-479B-B5B4-26E7FA2560ED wds:Q46708832-0E902801-4507-4DB0-9AE7-16E1689422EB wds:Q46708832-12523114-36F8-4C21-8A11-CD0C4390FF92 wds:Q46708832-2993655C-B82A-41D8-8DCA-4E2959B8A563
wdt:P50
wd:Q47264894 wd:Q5387640 wd:Q64431345 wd:Q28468989 wd:Q16027739 wd:Q88161889 wd:Q24248288 wd:Q60546641 wd:Q42226825 wd:Q60503412 wd:Q37372644 wd:Q7172602
p:P1476
wds:Q46708832-CEDC6E73-9036-44DE-AD0A-42424A73D7EE
wdt:P1476
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
p:P304
wds:Q46708832-7B5E21FD-FB38-423F-827F-EF9FA42CF79C
wdt:P304
401
p:P31
wds:Q46708832-F8E14582-5C2B-4AEC-92C2-94B71B24DE88
wdt:P31
wd:Q13442814
p:P921
wds:Q46708832-15EBD4B6-3D34-4123-B4E6-742E81BBA5F4
wdt:P921
wd:Q410237
p:P698
wds:Q46708832-7D2AD0A3-EE81-4DB5-B671-EBAA42591E2E
wdtn:P698
n11:16169314
wdt:P698
16169314
p:P1433
wds:Q46708832-BC91EC67-B85C-4CA2-82C8-A0586AA3AC1E
wdt:P1433
wd:Q2227156
p:P433
wds:Q46708832-94217A7D-D525-4CDD-9CDC-22223E88416E
p:P478
wds:Q46708832-8499A1EA-3556-406A-9D3A-3EE8101CDAD3
wdt:P433
3
wdt:P478
150
p:P356
wds:Q46708832-9ECC788E-2B18-4F44-A2DB-CD144E66F07F
wdtn:P356
n5:J.AHJ.2005.03.017
wdt:P356
10.1016/J.AHJ.2005.03.017